ABSTRACT
Introduction: Sleep apnoea syndrome (SAS), is a sleep disorder and characterized by very shallow breath or repetitive cessation of breathing during sleep (sleep apnoea). At present, no pharmacological agents have proved to be successful against SAS, and the syndrome is only treated by surgical interventions or devices such as intraoral mandibular advancement and Continuous Positive Air Pressure (CPAP) techniques.
Areas covered: two patents published in 2016 describing a new pharmacological application of inhibitors of the metalloenzyme Carbonic Anhydrases (CAs, EC 4.2.1.1) and an aldosterone antagonist agents and their therapeutic application was analysed.
Expert opinion: The present patents address an important healthcare problem by proposing a new pharmacological approach and may represent a valid alternative for the treatment of sleep apnea. One of the interesting points raised by these patents is the advantage of using a minor quantity of pharmacological agents in combination than active agent alone and consequently, a significant reduction of the side effects.
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Reviewer disclosures
Peer reviewers on this manuscript have no relevant financial or other relationships to disclose